{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:00:18Z","timestamp":1790611218590,"version":"4.1.0"},"reference-count":92,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,14]]},"DOI":"10.14797\/mdcvj.1050","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T11:15:11Z","timestamp":1647256511000},"page":"59-72","source":"Crossref","is-referenced-by-count":51,"title":["Cardiac Amyloidosis Treatment"],"prefix":"10.14797","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3024-9563","authenticated-orcid":false,"given":"Lily K.","family":"Stern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-6750","authenticated-orcid":false,"given":"Jignesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"issue":"4","key":"key20220314071506_B1","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/ehf2.13443","article-title":"Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature","volume":"8","year":"2021","journal-title":"ESC Heart Failure"},{"issue":"4","key":"key20220314071506_B2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11912-021-01028-8","article-title":"Updates in Cardiac Amyloidosis Diagnosis and Treatment","volume":"23","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"36","key":"key20220314071506_B3","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"key20220314071506_B4","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","year":"2020","journal-title":"Blood"},{"issue":"4","key":"key20220314071506_B5","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","article-title":"Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis","volume":"103","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"key20220314071506_B6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-020-0306-5","article-title":"A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis","volume":"10","year":"2020","journal-title":"Blood Cancer J"},{"issue":"9","key":"key20220314071506_B7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","article-title":"Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis","volume":"18","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"suppl_1","key":"key20220314071506_B8","first-page":"A14407","article-title":"Abstract 14407: Regression of Cardiac AL Amyloid by Cardiovascular Magnetic Resonance","volume":"134","year":"2016","journal-title":"Circulation"},{"issue":"13","key":"key20220314071506_B9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"key20220314071506_B10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","year":"2019","journal-title":"Blood"},{"issue":"28","key":"key20220314071506_B11","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"key20220314071506_B12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"key20220314071506_B13","unstructured":"Genmab.com [Internet]. Copenhagen, Denmark; Genmab; c 2022. Genmab Announces that Janssen has been granted U.S. FDA approval for DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) for patients with newly diagnosed light-chain (al) amyloidosis; 2021 Jan 15 [cited 2022 Jan 5]. Available from: https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-announces-janssen-has-been-granted-us-fda-approval"},{"key":"key20220314071506_B14","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis; 2021 Oct 7 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04131309"},{"issue":"5","key":"key20220314071506_B15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjh.16122","article-title":"Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy","volume":"187","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"key20220314071506_B16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","year":"2021","journal-title":"Blood Cancer J"},{"issue":"18","key":"key20220314071506_B17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","year":"2020","journal-title":"Blood"},{"issue":"18","key":"key20220314071506_B18","first-page":"1541","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","year":"2020"},{"issue":"1","key":"key20220314071506_B19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-019-0266-9","article-title":"Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis","volume":"10","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"key20220314071506_B20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","year":"2010","journal-title":"Am J Hematol"},{"issue":"Supplement_1","key":"key20220314071506_B21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2019-124409","article-title":"Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician\u2019s Choice of Therapy in Patients (Pts) with Relapsed\/Refractory Primary Systemic AL Amyloidosis (RRAL)","volume":"134","year":"2019","journal-title":"Blood"},{"key":"key20220314071506_B22","unstructured":"Reuters.com [Internet]. Canary Wharf, London: Reuters;c2022. BRIEF: Prothena Discontinues Development of NEOD001 for AL Amyloidosis; 2018 Apr 13 [cited 2022 Jan 5]. Available from: https:\/\/www.reuters.com\/article\/brief-prothena-discontinues-development-idCNASC09WS6"},{"issue":"Supplement 1","key":"key20220314071506_B23","first-page":"26","article-title":"Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)","volume":"136","year":"2020","journal-title":"Blood"},{"key":"key20220314071506_B24","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine;c 2022. A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis;2021 Dec 7 [cited 2022Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04512235"},{"key":"key20220314071506_B25","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis; 2021 Dec 7 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04504825"},{"issue":"6","key":"key20220314071506_B26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"key20220314071506_B27","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis; 2018 Mar 21 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT01511263"},{"key":"key20220314071506_B28","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL); 2017 Oct 17 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02015312"},{"issue":"3","key":"key20220314071506_B29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12185-016-2112-1","article-title":"Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis","volume":"105","year":"2017","journal-title":"Int J Hematol"},{"issue":"25","key":"key20220314071506_B30","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","year":"2011","journal-title":"Blood"},{"issue":"23","key":"key20220314071506_B31","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","year":"2014","journal-title":"Blood"},{"issue":"3","key":"key20220314071506_B32","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","year":"2017","journal-title":"Blood Cancer J"},{"issue":"21","key":"key20220314071506_B33","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation","volume":"120","year":"2012","journal-title":"Blood"},{"issue":"1","key":"key20220314071506_B34","first-page":"8","article-title":"Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial","volume":"145","year":"2022"},{"key":"key20220314071506_B35","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy; 2021 Jan 26 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03474458"},{"issue":"1","key":"key20220314071506_B36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"key20220314071506_B37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","year":"2019","journal-title":"Circulation"},{"key":"key20220314071506_B38","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy); 2022 Jan 13 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03997383"},{"issue":"1","key":"key20220314071506_B39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"key20220314071506_B40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","year":"2020","journal-title":"Amyloid"},{"key":"key20220314071506_B41","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients; 2020 Dec 7 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03702829"},{"issue":"3","key":"key20220314071506_B42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)","volume":"34","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"key20220314071506_B43","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; 2022 Jan 13 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04153149"},{"key":"key20220314071506_B44","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM); 2022 Jan 11 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04136171"},{"issue":"6","key":"key20220314071506_B45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"key20220314071506_B46","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","year":"2006","journal-title":"Amyloid"},{"issue":"6","key":"key20220314071506_B47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","year":"2012","journal-title":"Congest Heart Fail"},{"issue":"4","key":"key20220314071506_B48","article-title":"TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis","volume":"11","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"2","key":"key20220314071506_B49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","year":"2015","journal-title":"Amyloid"},{"issue":"sup1","key":"key20220314071506_B50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13506129.2019.1593133","article-title":"The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition","volume":"26","year":"2019","journal-title":"Amyloid"},{"issue":"11","key":"key20220314071506_B51","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"key20220314071506_B52","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy","volume":"141","year":"2020","journal-title":"Circulation"},{"issue":"Suppl_1","key":"key20220314071506_B53","first-page":"A13847","article-title":"Abstract 13847: Differential Transthyretin Binding, Kinetic Stability and Additive Ex Vivo Stabilization by AG10 Compared to Tafamidis","volume":"140","year":"2019","journal-title":"Circulation"},{"key":"key20220314071506_B54","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy; 2021 Dec 30 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03860935"},{"issue":"22","key":"key20220314071506_B55","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","article-title":"Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity","volume":"583","year":"2009","journal-title":"FEBS Lett"},{"issue":"1","key":"key20220314071506_B56","article-title":"Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: \u201cin vivo\u201d evidence from FAP mice models","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key20220314071506_B57","first-page":"6319","article-title":"Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study","volume":"9","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"key20220314071506_B58","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s00392-015-0826-3","article-title":"Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study","volume":"104","year":"2015","journal-title":"Clin Res Cardiol"},{"issue":"10","key":"key20220314071506_B59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"key20220314071506_B60","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","year":"2010","journal-title":"J Transl Med"},{"issue":"Suppl 1","key":"key20220314071506_B61","first-page":"34","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","year":"2012","journal-title":"Amyloid"},{"issue":"sup1","key":"key20220314071506_B62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","article-title":"Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis","volume":"24","year":"2017","journal-title":"Amyloid"},{"issue":"3","key":"key20220314071506_B63","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","article-title":"Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis","volume":"25","year":"2019","journal-title":"J Card Fail"},{"key":"key20220314071506_B64","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy\/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin; 2020 May 14 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03481972"},{"key":"key20220314071506_B65","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis; 2020 Aug 20 [cited 2022 Feb 19]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03336580"},{"issue":"1","key":"key20220314071506_B66","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","year":"2021","journal-title":"Nat Commun"},{"key":"key20220314071506_B67","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy; 2021 Aug 10 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04360434"},{"issue":"12","key":"key20220314071506_B68","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"key20220314071506_B69","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698;2019 Oct 16 [cited 2022 Jan 31]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03044353"},{"issue":"2","key":"key20220314071506_B70","first-page":"186","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","year":"2015"},{"issue":"1","key":"key20220314071506_B71","first-page":"e7","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"key20220314071506_B72","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14656566.2019.1574746","article-title":"Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases","volume":"20","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"key20220314071506_B73","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMcp074189","article-title":"Clinical practice. Neurogenic orthostatic hypotension","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"issue":"13 Pt 1","key":"key20220314071506_B74","first-page":"1645","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","year":"1985","journal-title":"Am J Cardiol"},{"issue":"11","key":"key20220314071506_B75","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","year":"2019","journal-title":"Heart Rhythm"},{"issue":"11","key":"key20220314071506_B76","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"key20220314071506_B77","first-page":"562","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","year":"2016","journal-title":"Int J Cardiol"},{"issue":"3","key":"key20220314071506_B78","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","year":"2019","journal-title":"Amyloid"},{"issue":"6","key":"key20220314071506_B79","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","year":"1981","journal-title":"Circulation"},{"issue":"2","key":"key20220314071506_B80","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","year":"2018","journal-title":"Amyloid"},{"issue":"12","key":"key20220314071506_B81","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis","volume":"5","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"issue":"21","key":"key20220314071506_B82","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","year":"2007","journal-title":"Circulation"},{"issue":"38","key":"key20220314071506_B83","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"issue":"2","key":"key20220314071506_B84","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis","volume":"77","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"29","key":"key20220314071506_B85","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","volume":"41","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"key20220314071506_B86","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.healun.2013.01.987","article-title":"Left ventricular device implantation for advanced cardiac amyloidosis","volume":"32","year":"2013","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"key20220314071506_B87","article-title":"Mechanical circulatory support for cardiac amyloidosis","volume":"33","year":"2019","journal-title":"Clin Transplant"},{"issue":"10","key":"key20220314071506_B88","article-title":"United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis","volume":"34","year":"2020","journal-title":"Clin Transplant"},{"issue":"5","key":"key20220314071506_B89","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","year":"2018","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"key20220314071506_B90","article-title":"Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era","volume":"35","year":"2021","journal-title":"Clin Transplant"},{"issue":"5","key":"key20220314071506_B91","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.healun.2014.09.006","article-title":"Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy","volume":"34","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"key20220314071506_B92","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1111\/ajt.15487","article-title":"Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis","volume":"19","year":"2019","journal-title":"Am J Transplant"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T11:16:24Z","timestamp":1647256584000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1050\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3,14]]}},"alternative-id":["10.14797\/mdcvj.1050"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1050","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}